Investors & Partners

Partners and Collaborators

SignalChem is developing a solid portfolio of first-in-class or best-in-class treatments that target multiple mechanisms that underlie the non-responsiveness and resistance to targeted therapies. We work with strategic partners at every step of the way - from the organizations who are interested in licensing our assets, to the contract research organizations and academics with whom we conduct our studies.


Our collaborative network includes world leaders in the pharmaceutical industry and leading scientists from renowned institutions such as BC Cancer Research Center, University of British Columbia, and etc.



Please contact info@signalchemcorp.com regarding licensing opportunities

Press Releases


SignalChem Announces Patients Enrollment in Clinical Trial of AXL Inhibitor SLC-391 in Combination with KEYTRUDA® (pembrolizumab) for Advanced or Metastatic Non-Small Cell Lung Cancer

August 15, 2023
Continue Reading

SignalChem Lifesciences Corp. is pleased to announce the enrollment of the first three patients in its phase Ib clinical trial in The United States and Canada, evaluating the efficacy and safety of AXL inhibitor SLC-391 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).


AXL is a receptor tyrosine kinase that has been implicated in tumor growth and metastasis, immune evasion, and resistance to therapy in various cancers, including NSCLC. By inhibiting AXL signaling, SLC-391 has the potential to enhance the anti-tumor immune response and sensitize cancer cells to immune checkpoint inhibitors like KEYTRUDA® (pembrolizumab).


"We are excited to initiate this clinical trial exploring the combination of AXL inhibitor SLC-391 with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer," said Mr. Jun Yan, President and CEO of SignalChem. "We believe that targeting AXL signaling alongside immune checkpoint inhibition holds promise for improving treatment outcomes in this challenging disease."


The multicenter, open-label phase 1b study will enroll up to 30 patients with advanced or metastatic NSCLC. The objectives include determining the safety and recommended Phase 2 dose (RP2D) of SLC-391 in combination with pembrolizumab and evaluating the pharmacokinetics (PK) of SLC-391 when administered in combination with pembrolizumab.


SignalChem is committed to advancing the field of oncology and addressing the unmet needs of cancer patients through its innovative pipeline of targeted therapies. The initiation of this clinical trial represents a significant milestone in the company's mission to develop novel treatment options for individuals battling advanced or metastatic non-small cell lung cancer.


KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.


About Lung Cancer


Lung cancer, which forms in the tissues of the lungs, typically within cells lining the air passages, is the leading cause of cancer death worldwide. Each year, more people die of lung cancer than colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. The overall 5-year survival rate for NSCLC is 24%, ranging from 61% for localized NSCLC to 6% for metastatic disease.


About SLC-391


Lung cancer, which forms in the tissues of the lungs, typically within cells lining the air passages, is the leading cause of cancer death worldwide. Each year, more people die of lung cancer than colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. The overall 5-year survival rate for NSCLC is 24%, ranging from 61% for localized NSCLC to 6% for metastatic disease.


About SignalChem


SignalChem Lifesciences Corporation (“SLC”), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. SLC has a strong small-molecule drug development pipeline (https://signalchemlifesciences.com/pipeline.php). Our novel targeted compounds are designed internally by a group of scientists with expertise and experience in kinase biology and drug discovery. SLC is seeking strategic partners to aid in bringing our clinical-stage drug pipeline to the market.


SignalChem (https://www.signalchem.com), a separate division from SignalChem Lifesciences, is a biotech company focused on the research, development and production of innovative and high-quality human recombinant cell signaling products. Throughout the years, SignalChem has capitalized on its core expertise in cellular signaling, molecular biology and protein biochemistry to generate more than 2,000 functional protein products.


SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.


For more information, please visit https://www.signalchemlifesciences.com.


Forward-Looking Statements and Information


This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.


Contact:


Zaihui Zhang, PhD

CSO, VP R & D

zzhang@signalchemcorp.com

+ 604 232 4600 ext. 114


SignalChem Receives US FDA Clearance of Investigational New Drug Application for Clinical Trial of AXL Inhibitor SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer

March 30th, 2023
Continue Reading

SignalChem Lifesciences Corp. today announced that it has received US Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) Application for its single-arm, open-label, phase 1b/2 Study of SLC-391, an AXL inhibitor, in combination with KEYTRUDA® (pembrolizumab) in subjects with advanced or metastatic non-small cell lung cancer (NSCLC).


AXL, a member of the TAM family protein tyrosine kinases (Tyro3, AXL and Mer). Over-expression of AXL leads to growth and spread of tumors, metastasis, EMT, tumor microenvironment deregulation, immune evasion, and resistance to multiple anticancer therapies including PD(L)-1. SLC-391 is a clinical stage small molecule AXL inhibitor with high potency, selectivity and desirable pharmaceutical properties. SLC-391 disrupts cell division, inhibiting tumor growth and causing cancer cells to die.


The trial will evaluate the safety and efficacy of SLC-391 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). SignalChem and Merck (known as MSD outside the US and Canada) plan to conduct the study in multiple cancer centers in the US and Canada (SKYLITE trial).


"We are very pleased to receive IND clearance from the US FDA to proceed with this clinical trial of SLC-391 in combination with KEYTRUDA® (pembrolizumab)," said Mr. Jun Yan, President and CEO of SignalChem. "This marks a significant milestone in our efforts to develop innovative treatments for patients with advanced or metastatic NSCLC, and we look forward to advancing this promising therapy through clinical development."


SignalChem is committed to developing innovative treatments for cancer and will continue to work with healthcare providers, patients, and regulatory agencies to bring new therapies to market.


KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.


About Lung Cancer


Lung cancer, which forms in the tissues of the lungs, usually within cells lining the air passages, is the leading cause of cancer death worldwide. Each year, more people die of lung cancer than colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. The overall 5-year survival rate for NSCLC is 24%, ranging from 61% for localized NSCLC to 6% for metastatic disease.


About SLC-391


SLC-391 is a potent, selective and orally bioavailable small molecule AXL inhibitor. Currently, phase I clinical trial is ongoing in Canada to evaluate the safety and tolerability of SLC-391 in cancer patients with solid tumour.


About SignalChem


SignalChem Lifesciences Corporation (“SLC”), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. SLC has a strong small-molecule drug development pipeline (https://signalchemlifesciences.com/pipeline.php). Our novel targeted compounds are designed internally by a group of scientists with expertise and experience in kinase biology and drug discovery. SLC is seeking strategic partners to aid in bringing our clinical-stage drug pipeline to the market.


SignalChem (https://www.signalchem.com), a separate division from SignalChem Lifesciences, is a biotech company focused on the research, development and production of innovative and high-quality human recombinant cell signaling products. Throughout the years, SignalChem has capitalized on its core expertise in cellular signaling, molecular biology and protein biochemistry to generate more than 2,000 functional protein products.


SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.


For more information, please visit https://www.signalchemlifesciences.com.


Forward-Looking Statements and Information


This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.


Contact:


Zaihui Zhang, PhD

CSO, VP R & D

zzhang@signalchemcorp.com

+ 604 232 4600 ext. 114


SignalChem Lifesciences Corp. Obtains NOL from Health Canada for Clinical Trial

March 3rd, 2023
Continue Reading

SignalChem Lifesciences Corp. Obtains NOL from Health Canada for Clinical Trial of AXL Inhibitor SLC-391 in Combination with KEYTRUDA (pembrolizumab) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer


Vancouver, British Columbia, March 3, 2023 – SignalChem Lifesciences Corp. today announced that it has received a No Objection Letter (NOL) from Health Canada for its clinical trial "A Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)".


AXL, a member of the TAM family protein tyrosine kinases (Tyro3, AXL and Mer). Over-expression of AXL leads to growth and spread of tumors, metastasis, EMT, tumor microenvironment deregulation, immune evasion, and resistance to multiple anticancer therapies including PD(L)-1. SLC-391 is a clinical stage small molecule AXL inhibitor with high potency, selectivity and desirable pharmaceutical properties. SLC-391 disrupts cell division, inhibiting tumor growth and causing cancer cells to die.


The trial will evaluate the safety and efficacy of SLC-391 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). SignalChem and Merck (known as MSD outside the US and Canada) plan to conduct the study in multiple cancer centers in the US and Canada (SKYLITE trial).


"We are thrilled to receive the NOL from Health Canada for our clinical trial," said Mr. Jun Yan, President and CEO of SignalChem. "This marks an important milestone in our mission to bring innovative treatments to patients with NSCLC. We are confident SLC-391 in combination with KEYTRUDA may have the potential to make a significant impact on the lives of those affected by this devastating disease. We appreciate the opportunity to work with Health Canada and our collaborators in advancing our clinical trial. We look forward to reporting the results of this study and advancing our mission to improve the lives of patients with cancer."


Health Canada's rigorous review process ensures that new treatments are safe and effective for Canadians. The NOL for this trial is a testament to the quality of the research and development conducted by SignalChem and the scientific and medical communities involved in its development.


SignalChem is committed to developing innovative treatments for cancer and will continue to work with healthcare providers, patients, and regulatory agencies to bring new therapies to market.


KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.


About Lung Cancer


Lung cancer, which forms in the tissues of the lungs, usually within cells lining the air passages, is the leading cause of cancer death worldwide. Each year, more people die of lung cancer than colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. The overall 5-year survival rate for NSCLC is 24%, ranging from 61% for localized NSCLC to 6% for metastatic disease.


About SLC-391


SLC-391 is a potent, selective and orally bioavailable small molecule AXL inhibitor. Currently, phase I clinical trial is ongoing in Canada to evaluate the safety and tolerability of SLC-391 in cancer patients with solid tumour.


About SignalChem


SignalChem Lifesciences Corporation (“SLC”), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. SLC has a strong small-molecule drug development pipeline (https://signalchemlifesciences.com/pipeline.php). Our novel targeted compounds are designed internally by a group of scientists with expertise and experience in kinase biology and drug discovery. SLC is seeking strategic partners to aid in bringing our clinical-stage drug pipeline to the market.


SignalChem (https://www.signalchem.com), a separate division from SignalChem Lifesciences, is a biotech company focused on the research, development and production of innovative and high-quality human recombinant cell signaling products. Throughout the years, SignalChem has capitalized on its core expertise in cellular signaling, molecular biology and protein biochemistry to generate more than 2,000 functional protein products.


SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.


For more information, please visit https://www.signalchemlifesciences.com.

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.


Contact:


Zaihui Zhang, PhD

CSO, VP R & D

zzhang@signalchemcorp.com

+ 604 232 4600 ext. 114


Xuanzhu and SignalChem Lifesciences Corporation Announce Collaboration and Licensing Agreement for SLC-391 in the Greater China Region

September 24, 2021
Continue Reading

Sihuan Pharmaceutical Holdings Group Ltd., together with its subsidiaries and SignalChem Lifesciences Corporation today announced that Sihuan Pharmaceutical Holdings Group Ltd subsidiary company Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu") and SignalChem Lifesciences Corporation ("SignalChem") have entered into an exclusive collaboration and licensing agreement for the clinical development and commercialization of SLC-391, a potent and selective AXL targeting inhibitor, in the Greater China region.

Under the terms of the agreement, Xuanzhu will pay to SignalChem an upfront fee of thirteen million US dollars (US$13,000,000). Additional development milestones and royalties have also been committed. The exclusive rights for SLC-391 for the field of oncology is for the Greater China region (Mainland China, Hong Kong, Macau and Taiwan).

AXL is a member of TAM (Tyro3, AXL, Mer) family of receptor tyrosine kinases. AXL along with its ligand GAS6 (growth arrest-specific gene 6) is highly expressed and activated in many malignant tumors, such as acute myeloid leukemia, kidney, pancreatic, breast, lung and ovarian cancer, etc. As one of the crucial signaling pathways promoting tumor growth and metastasis, immune escape and drug resistance, GAS6-AXL pathway is considered to be an attractive target for cancer treatment and has attracted widespread attention.

"The agreement with SignalChem will further advance Xuanzhu's pipeline in the solid tumor and hematoma space. The results from preclinical and phase 1 clinical development demonstrated SLC-391 superiority not only as SLC-391 has prominent single-agent activities in multiple solid and hematological tumors but also can potentially be administered with a variety of drugs under development at Xuanzhu. Both parties will use their respective resources to accelerate the clinical approval of SLC-391 in China,” said Ms. Xu Yanjun, Chairman of Xuanzhu. “Xuanzhu will continue to expand its efforts to develop and commercialize innovative drugs in the oncology field."

“Xuanzhu Biopharmaceutical, a subsidiary of Sihuan Pharmaceutical, is a highly innovative and progressive company,” commented by Mr. Jun Yan, the Chairman and President of SignalChem, “We are very pleased to establish a partnership with Xuanzhu. This licensing agreement is of great significance for SignalChem to further validate and expand SLC-391’s clinical superiority. This agreement will accelerate SLC-391’s development timeline to reach the market and provide more effective treatment alternatives for patients with cancer.” Mr. Jun Yan added, “the size of the agreement, including upfront, milestone and royalties, with Xuanzhu may be one of the largest agreements signed in Canada with a Chinese bio-pharma company for the Chinese territory rights, and we are looking forward to reaching all anticipated objectives. Furthermore, SignalChem will continue its efforts to expand and accelerate clinical development with SLC-391 for wider indications in even more geographic territories.”

About SLC-391

SLC-391 is a potent, highly selective and orally bioavailable small molecule AXL inhibitor. Preclinical investigational data shows SLC-391 is a superior AXL inhibitor and has the potential to become a first-in-class inhibitor. Phase I clinical study is currently underway in Canada. SignalChem has established a collaboration with Merck (MSD) to evaluate the efficacy of SLC-391 in combination with Keytruda® (pembrolizumab) for the treatment of advanced non-small cell lung cancer (NSCLC). In pre-clinical studies, SLC-391 demonstrated strong efficacy as a single agent or in combination with other approved drugs in multiple animal models for cancer. SLC-391 will be developed to undisclosed cancer indications as a single agent or in combination with other therapies.

About Xuanzhu

Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of Sihuan Pharmaceutical Holdings Group Ltd., is an innovative biopharmaceutical company rooted in China with a global perspective, focusing on tumors, metabolic diseases, infections, and other fields. It has a layout of the entire industry chain from drug discovery, preclinical research, clinical development, and production commercialization. Xuanzhu’s strengths reside in its detailed knowledge and expertise in the clinical development and regulatory approval processes in China. Xuanzhu has a clinical and regulatory team of over 300 people bringing expertise from numerous multinational pharmaceutical companies including J&J, Lilly, Merck, Novartis, Pfizer, and Roche. This combined with the most extensive sales and marketing capability in China, places Xuanzhu as the premier partner for those companies with innovative assets desiring to enter the China domestic market.

About SignalChem Lifesciences Corporation

SignalChem Lifesciences Corporation, headquartered in Richmond, British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. Its unique business model has been built upon four important pillars: Drug Discovery and Development, the Bioreagents and Research Services business, In-Vitro Diagnostic Reagent Development and Plant Biosynthesis Systems. We at SignalChem are a group of scientists with extraordinary expertise and experience in protein engineering and drug discovery who are working together cohesively to provide the best products and services to our customers around the world and to maximize the efficiency of our own drug discovery efforts.

Xuanzhu Forward-Looking Statements

These statements are only predictions based upon our current expectations and projections about future events. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Xuanzhu to be materially different from those expressed or implied by such forward-looking statements. Although Xuanzhu has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. You should not rely on forward-looking statements as a prediction of future events.

The assumptions used in the preparation of this statement although considered reasonable by Xuanzhu at the time of preparation, may prove to be incorrect. Recipients are cautioned that the information is based on assumptions as to many factors and that actual results may vary from the results projected and such variations may be material. Accordingly, readers should not place undue reliance on any forward-looking statements contained herein. Xuanzhu does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

SignalChem’s Forward-Looking Statements

These statements contain forward-looking statements, including statements about SignalChem’s business strategy, product development, regulatory matters, manufacturing plans, and intellectual property plans. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. SignalChem’s business is subject to numerous risks and uncertainties. SignalChem has never commercialized any drug products and it is uncertain whether its product candidates under development will become effective treatments. SignalChem’s product candidates are still in an early stage of development, have not completed clinical development and have not received regulatory approval for commercialization. SignalChem may not actually achieve the plans, projections, or expectations set forth in its forward-looking statements. Actual results or events could differ materially from the plans, projections, and expectations set forth in its forward-looking statements, as a result of the risks affecting its business.

Contact:

Xuanzhu Biopharmaceutical Co., Ltd.

Deyan Hou

Business Development

Houdeyan@xuanzhubio.com

+86 186 1269 2542

SignalChem Lifesciences Corporation

Zaihui Zhang, PhD

CSO, VP R & D

zzhang@signalchemcorp.com

+ 604 232 4600 ext. 114